Outlook Therapeutics is trading at $1.47 (+6.52%) in pre-market as the stock recovers from recent selling pressure linked to dilution concerns.
- Shares had been weighed down since a July 17 filing registered approximately 17.3 million existing shares for resale, creating a supply overhang.
- The recovery is being supported by broader market strength, with firm Nasdaq futures and positive sentiment across the biotech sector.